M. Rizzolio

发表

Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2015, ACS medicinal chemistry letters.

Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development.

P. Bonaventure, Kiev S. Ly, T. Lovenberg, 2010, Bioorganic & medicinal chemistry letters.

Covalently bound fatty acids in membrane proteins of some sponges

C. Djerassi, S. Beaulieu, E. Ayanoglu, 1990 .

Spontaneous Gelation of a Novel Histamine H4 Receptor Antagonist in Aqueous Solution

M. Peterson, Magali B. Hickey, Alexey Popov, 2011, Pharmaceutical Research.

The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2016, Bioorganic & medicinal chemistry letters.

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol- 2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor

S. Bembenek, T. Mirzadegan, M. Rosen, 2011 .

Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

S. Bembenek, T. Mirzadegan, M. Rosen, 2011, Molecular Pharmacology.

Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases

Jiejun Wu, M. Rosen, Y. Yang, 2009, Journal of biomolecular screening.

Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.

P. Bonaventure, Kiev S. Ly, T. Lovenberg, 2015, Journal of medicinal chemistry.

Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia

P. Bonaventure, T. Lovenberg, N. Carruthers, 2015, The Journal of Pharmacology and Experimental Therapeutics.

The cholecystokinin CCK2 receptor antagonist, JNJ‐26070109, inhibits gastric acid secretion and prevents omeprazole‐induced acid rebound in the rat

T. Barrett, N. Shankley, M. Rizzolio, 2012, British journal of pharmacology.

Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2012, ACS medicinal chemistry letters.

Screening And Design Of Tumor Necrosis Factor-: Converting Enzyme Inhibitors

M. Lambert, T. Tippin, R. Wiethe, 2000 .

N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.

J. Warner, M. Lambert, T. Tippin, 2001, Bioorganic & medicinal chemistry letters.

JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability

J. Pyati, T. Barrett, N. Shankley, 2011, Journal of Pharmacology and Experimental Therapeutics.

Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.

P. Bonaventure, C. Dvorak, T. Lovenberg, 2020, ACS medicinal chemistry letters.

1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase.

Sandy J. Wilson, M. Karbarz, S. Chaplan, 2014, Bioorganic & medicinal chemistry letters.

Immunolocalization of novel corticomedullary tubule injury markers in Cynomolgus monkeys treated with amphotericin B.

Yunhai Zhang, M. Rizzolio, M. Sonee, 2017, The Journal of toxicological sciences.

1,2-elimination of alcohol from homoallyl ethers under the influence of mixed metal bases

C. Margot, M. Schlosser, M. Rizzolio, 1990 .

Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE)+

M. Lambert, A. Musso, M. A. Leesnitzer, 2001 .

Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine.

M. Rizzolio, M. Sonee, J. Ma, 2016, Toxicology research.

Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.

M. Rosen, C. Woods, M. Hack, 2006, Journal of medicinal chemistry.

Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.

M. Peterson, Hong Ao, A. Bhattacharya, 2009, Bioorganic & medicinal chemistry letters.

Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.

M. Karbarz, S. Chaplan, J. Keith, 2014, Bioorganic & medicinal chemistry letters.

Pyrazole-based arylalkyne cathepsin S inhibitors. Part III: modification of P4 region.

John J. M. Wiener, Lars Karlsson, James P. Edwards, 2013, Bioorganic & medicinal chemistry letters.

Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.

N. Carruthers, A. Dubin, Sui-Po Zhang, 2005, Journal of medicinal chemistry.

Heteroarylureas with Fused Bicyclic Diamine Cores as Inhibitors of Fatty Acid Amide Hydrolase.

M. Karbarz, S. Chaplan, J. Keith, 2020, Bioorganic & medicinal chemistry letters.

3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a Novel, Potent, and Selective Cholecystokinin 1 Receptor Antagonist: In Vitro and in Vivo Pharmacological Comparison with Dexloxiglumide

J. Pyati, T. Barrett, N. Shankley, 2007, Journal of Pharmacology and Experimental Therapeutics.

Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist.

Hong Ao, A. Bhattacharya, A. Wickenden, 2011, European journal of pharmacology.

1,2-diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties.

Hong Ao, A. Bhattacharya, A. Wickenden, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.

W. Chai, Jennifer D. Venable, J. Edwards, 2020, Journal of medicinal chemistry.

Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.

M. Karbarz, S. Chaplan, J. Keith, 2012, ACS medicinal chemistry letters.

Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation

Jennifer D. Venable, Thomas B. Sundberg, M. Rives, 2023, Proceedings of the National Academy of Sciences of the United States of America.